JP2006522800A - パーキンソン病を治療するための方法 - Google Patents

パーキンソン病を治療するための方法 Download PDF

Info

Publication number
JP2006522800A
JP2006522800A JP2006506582A JP2006506582A JP2006522800A JP 2006522800 A JP2006522800 A JP 2006522800A JP 2006506582 A JP2006506582 A JP 2006506582A JP 2006506582 A JP2006506582 A JP 2006506582A JP 2006522800 A JP2006522800 A JP 2006522800A
Authority
JP
Japan
Prior art keywords
parkinson
disease
safinamide
composition
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006506582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522800A5 (OSRAM
Inventor
ルッジェーロ，ファリエッロ
カッタネオ，カルロ
サルヴァティ，パトリシア
ベナッティ，ルーカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006522800(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Publication of JP2006522800A publication Critical patent/JP2006522800A/ja
Publication of JP2006522800A5 publication Critical patent/JP2006522800A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006506582A 2003-04-11 2004-04-08 パーキンソン病を治療するための方法 Pending JP2006522800A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012273371A Division JP2013067647A (ja) 2003-04-11 2012-12-14 パーキンソン病を治療するための方法

Publications (2)

Publication Number Publication Date
JP2006522800A true JP2006522800A (ja) 2006-10-05
JP2006522800A5 JP2006522800A5 (OSRAM) 2007-06-28

Family

ID=33159845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006506582A Pending JP2006522800A (ja) 2003-04-11 2004-04-08 パーキンソン病を治療するための方法
JP2012273371A Pending JP2013067647A (ja) 2003-04-11 2012-12-14 パーキンソン病を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012273371A Pending JP2013067647A (ja) 2003-04-11 2012-12-14 パーキンソン病を治療するための方法

Country Status (28)

Country Link
US (3) US8283380B2 (OSRAM)
EP (2) EP2070526B1 (OSRAM)
JP (2) JP2006522800A (OSRAM)
KR (2) KR101129015B1 (OSRAM)
CN (2) CN1771030A (OSRAM)
AR (1) AR044007A1 (OSRAM)
AT (1) ATE435012T1 (OSRAM)
AU (1) AU2004228782B2 (OSRAM)
BR (1) BRPI0409364A (OSRAM)
CA (1) CA2523188C (OSRAM)
CY (3) CY1109295T1 (OSRAM)
DE (1) DE602004021790D1 (OSRAM)
DK (2) DK2070526T3 (OSRAM)
ES (2) ES2454272T3 (OSRAM)
FR (1) FR15C0054I2 (OSRAM)
HU (1) HUS1500043I1 (OSRAM)
IL (2) IL171331A (OSRAM)
LU (1) LU92782I2 (OSRAM)
MX (1) MXPA05010873A (OSRAM)
NL (1) NL300752I2 (OSRAM)
NO (3) NO334316B1 (OSRAM)
NZ (1) NZ542910A (OSRAM)
PL (2) PL1613296T3 (OSRAM)
PT (2) PT2070526E (OSRAM)
RU (1) RU2342929C2 (OSRAM)
SI (2) SI1613296T1 (OSRAM)
TW (1) TWI340640B (OSRAM)
WO (1) WO2004089353A2 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
JP2010529969A (ja) * 2007-06-15 2010-09-02 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換２−［２−（フェニル）エチルアミノ］アルカンアミド誘導体ならびにナトリウムおよび／またはカルシウムチャネル調節剤としてのこれらの使用
JP2011522035A (ja) * 2008-06-06 2011-07-28 ファーマ ツゥ ビー リミテッド パーキンソン病治療医薬組成物
JP2013509359A (ja) * 2009-10-29 2013-03-14 重▲慶▼医葯工▲業▼研究院有限責任公司 安定なラサギリン組成物
JP2019510088A (ja) * 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1963280B1 (en) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
DK2474521T3 (en) 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
KR101593627B1 (ko) 2007-12-11 2016-02-11 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 ２­［４­（３­ 또는 ２­플루오로벤질옥시）벤질아미노］프로판아미드의 제조방법
CA2707646C (en) * 2007-12-19 2016-09-13 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
NZ589470A (en) * 2008-06-02 2012-08-31 Generics Uk Ltd A process for the preparation of rasagiline and its analogues
AU2009254927B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
NZ602648A (en) 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013081685A1 (en) 2011-08-19 2013-06-06 The Trustees Of Princeton University C-halogen bond formation
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
BR112015009088A2 (pt) 2012-10-22 2017-07-04 Civitas Therapeutics Inc formulações de levodopa para alívio rápido da doença de parkinson.
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
AU2014391721B2 (en) * 2014-04-21 2020-07-16 Merz Pharmaceuticals, Llc Rapid relief of motor fluctuations in Parkinson's Disease
CA2963371C (en) * 2014-10-02 2020-06-02 Korea Institute Of Science And Technology Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
WO2017032874A1 (en) * 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) * 2017-01-14 2018-07-19 Mischley Laurie Kathern Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
US11234961B2 (en) * 2017-08-17 2022-02-01 Zi-Qiang Gu Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
MX2020004403A (es) 2017-11-02 2020-08-06 Zambon Spa Composiciones farmaceuticas que comprenden safinamida.
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
KR20220074895A (ko) * 2019-09-12 2022-06-03 어치브 라이프 사이언시즈, 인크. 필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물
LU101477B1 (en) * 2019-11-12 2021-05-14 Univ Luxembourg An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
US20230181508A1 (en) * 2020-08-31 2023-06-15 Purdue Pharma L.P. Compositions and methods for levodopa delivery
WO2022192173A1 (en) * 2021-03-08 2022-09-15 Prothena Biosciences Limited Treatment of parkinson's disease
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500215A (ja) * 1989-05-25 1992-01-16 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー Ｎ―フェニルアルキル置換α―アミノカルボキシアミド誘導体およびその製造方法
JP2000500732A (ja) * 1995-07-27 2000-01-25 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
WO2003018060A1 (fr) * 2001-08-29 2003-03-06 Aventis Pharma S.A. Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
CA1336169C (en) 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ES2211904T3 (es) * 1995-05-26 2004-07-16 Pfizer Inc. Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500215A (ja) * 1989-05-25 1992-01-16 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー Ｎ―フェニルアルキル置換α―アミノカルボキシアミド誘導体およびその製造方法
JP2000500732A (ja) * 1995-07-27 2000-01-25 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
WO2003018060A1 (fr) * 2001-08-29 2003-03-06 Aventis Pharma S.A. Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6010054466; '"Ｎｅｗｒｏｎ　Ｒｅｌｅａｓｅｓ　Ｐｏｓｉｔｉｖｅ　Ｐｒｅｌｉｍｉｎａｒｙ　Ｐｈａｓｅ　ＩＩ　Ｄａｔａ　Ｆｏｒ　Ｓａｆｉｎａｍｉｄｅ　ｉｎ　Ｐａｒｋｉｎｓｏｎ'ｓ　Ｄｉｓｅａｓｅ"' Ｐｒｅｓｓ　Ｒｅｌｅａｓｅ　［ｏｎ　ｌｉｎｅ］ , 20030109, Ｎｅｗｒｏｎ　Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ *
JPN6010054467; Ｆｒｅｄｒｉｋｓｓｏｎ　Ａ，　ｅｔ　ａｌ．: '"Ｅｆｆｅｃｔｓ　ｏｆ　ｃｏ-ａｄｍｉｎｉｓｔｒａｔｉｏｎ　ｏｆ　ａｎｔｉｃｏｎｖｕｌｓａｎｔ　ａｎｄ　ｐｕｔａｔｉｖｅ　ａｎｔｉｃｏｎｖｕｌｓｉｖｅ　ａｇｅｎｔｓ　ａｎｄ　ｓｕｂ-／ｓｕｐｒａｔｈｒ' Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒａｌ　Ｔｒａｎｓｍｉｓｓｉｏｎ Ｖｏｌ．　１０６，　Ｎｏ．　９-１０, 199910, ｐｐ．　８８９-９０９ *
JPN6010054468; Ｃｈａｚｏｔ　ＰＬ: '"Ｓａｆｉｎａｍｉｄｅ　（Ｎｅｗｒｏｎ　Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ）"' Ｃｕｒｒｅｎｔ　ｏｐｉｎｉｏｎ　ｉｎ　ｉｎｖｅｓｔｉｇａｔｉｏｎａｌ　ｄｒｕｇｓ Ｖｏｌ．　２，　Ｎｏ．　６, 200106, ｐｐ．　８０９-８１３ *
JPN6010054470; Ｍｉｌｌａｎ　ＭＪ，　ｅｔ　ａｌ．: '"Ｄｉｆｆｅｒｅｎｔｉａｌ　Ａｃｔｉｏｎｓ　ｏｆ　Ａｎｔｉｐａｒｋｉｎｓｏｎ　Ａｇｅｎｔｓ　ａｔ　Ｍｕｌｔｉｐｌｅ　Ｃｌａｓｓｅｓ　ｏｆ　Ｍｏｎｏａｍｉｎｅｒｇｉｃ　Ｒｅｃｅｐｔｏｒ．　Ｉ．　Ａ　Ｍｕ' Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｐｈａｒｍａｃｏｌｏｇｙ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｔｈｅｒａｐｅｕｔｉｃｓ Ｖｏｌ．　３０３，　Ｎｏ．　２, 20021101, ｐｐ．　７９１-８０４ *
JPN6010054471; 水田英二: '"酵素阻害薬の有用性"' ＢＲＡＩＮ　ＭＥＤＩＣＡＬ Ｖｏｌ．　１４，　Ｎｏ．　２, 200206, ｐｐ．　１４５-１４９ *
JPN6011045711; 財団法人日本医薬情報センター編: 医療薬日本医薬品集２０００年版 , 19991025, ｐ．　２１５４-２１５７, 薬業時報社 *
JPN6011045713; Ｋｏｌｌｅｒ　ＷＣ，　ｅｔ　ａｌ．: '"Ｔｒｅａｔｉｎｇ　ｍｏｔｏｒ　ｆｌｕｃｔｕａｔｉｏｎｓ　ｗｉｔｈ　ｃｏｎｔｒｏｌｌｅｄ-ｒｅｌｅａｓｅ　ｌｅｖｏｄｏｐａ　ｐｒｅｐａｒａｔｉｏｎｓ"' Ｎｅｕｒｏｌｏｇｙ Ｖｏｌ．　４４，　Ｎｏ．　７，　Ｓｕｐｐｌ．　６, 199407, ｐ．　Ｓ２３-２８ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
JP2010529969A (ja) * 2007-06-15 2010-09-02 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換２−［２−（フェニル）エチルアミノ］アルカンアミド誘導体ならびにナトリウムおよび／またはカルシウムチャネル調節剤としてのこれらの使用
JP2011522035A (ja) * 2008-06-06 2011-07-28 ファーマ ツゥ ビー リミテッド パーキンソン病治療医薬組成物
JP2013509359A (ja) * 2009-10-29 2013-03-14 重▲慶▼医葯工▲業▼研究院有限責任公司 安定なラサギリン組成物
US8859624B2 (en) 2009-10-29 2014-10-14 Chongqing Pharmaceutical Research Institute Co., Ltd. Stable rasagiline composition
JP2019510088A (ja) * 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法

Also Published As

Publication number Publication date
TWI340640B (en) 2011-04-21
US9492410B2 (en) 2016-11-15
MXPA05010873A (es) 2006-03-21
NO335537B1 (no) 2014-12-22
RU2342929C2 (ru) 2009-01-10
NO2015018I1 (no) 2015-08-03
JP2013067647A (ja) 2013-04-18
TW200505423A (en) 2005-02-16
NO20054640D0 (no) 2005-10-10
BRPI0409364A (pt) 2006-04-25
KR20110070929A (ko) 2011-06-24
CY1109295T1 (el) 2014-07-02
KR20060010745A (ko) 2006-02-02
FR15C0054I1 (fr) 2015-11-09
RU2005131422A (ru) 2006-04-27
CY2015025I1 (el) 2016-04-13
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
EP2070526A1 (en) 2009-06-17
PT1613296E (pt) 2009-07-30
WO2004089353A8 (en) 2005-09-01
IL216403A (en) 2015-01-29
US20150150833A1 (en) 2015-06-04
FR15C0054I2 (fr) 2018-01-26
ES2454272T3 (es) 2014-04-10
EP2070526B1 (en) 2014-02-26
CN1771030A (zh) 2006-05-10
CN102274517A (zh) 2011-12-14
WO2004089353A2 (en) 2004-10-21
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
US8283380B2 (en) 2012-10-09
NZ542910A (en) 2007-10-26
PT2070526E (pt) 2014-03-31
CY2015025I2 (el) 2016-04-13
AU2004228782B2 (en) 2010-05-20
WO2004089353A3 (en) 2004-12-16
DK1613296T3 (da) 2009-10-05
NO2015018I2 (no) 2015-07-23
CA2523188A1 (en) 2004-10-21
PL2070526T3 (pl) 2014-08-29
EP1613296B1 (en) 2009-07-01
IL171331A (en) 2012-03-29
PL1613296T3 (pl) 2009-12-31
EP1613296A2 (en) 2006-01-11
HUS1500043I1 (hu) 2018-11-28
US8901176B2 (en) 2014-12-02
KR101129015B1 (ko) 2012-04-20
ATE435012T1 (de) 2009-07-15
AU2004228782A1 (en) 2004-10-21
CA2523188C (en) 2012-09-25
SI2070526T1 (sl) 2014-05-30
ES2326373T3 (es) 2009-10-08
NO334316B1 (no) 2014-02-03
DK2070526T3 (da) 2014-03-24
CN102274517B (zh) 2018-08-31
IL216403A0 (en) 2011-12-29
US20130053368A1 (en) 2013-02-28
AR044007A1 (es) 2005-08-24
NL300752I2 (OSRAM) 2016-07-05
NO20131417L (no) 2005-12-09
SI1613296T1 (sl) 2009-10-31
LU92782I2 (fr) 2015-09-22

Similar Documents

Publication Publication Date Title
JP2013067647A (ja) パーキンソン病を治療するための方法
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
JP6014702B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
US9278094B2 (en) Treatments for depression and other diseases with a low dose agent
RS56523B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
US20170231937A1 (en) Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
US20240197756A1 (en) Methods of treatment with neuroactive steroids
HK1161969B (zh) 治疗帕金森病的方法
HK1161969A (en) Methods for treatment of parkinson's disease
HK1087918A (en) Method for treatment of parkinson's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130218

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140726

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150304